Current trends of Cutaneous Adverse Drug Reactions in a tertiary care hospital in North India: a retrospective study
Keywords:
Cutaneous adverse drug reactions, CADR to vaccines, CADR to antifungalAbstract
Background- Cutaneous adverse drug reactions constitute 30 % of all the ADRs. With the constant flooding of the market with newer drugs and overzealous use of the over-the-counter drugs, it is important to keep a watch on the ADRs for better patient safety.
Aims and objectives- To analyze the reported cutaneous ADRs in a tertiary care hospital for their pattern, and suspected medications.
- To assess causality and severity of the CADR.
Material and methods- Retrospective study of CADRs reported from July 2020 to August 2023 was conducted. The severity of the reactions was assessed using the Modified Hartwig and Siegel scale and causality assessment was done using Naranjo’s causality assessment scale.
Results- Total 187 cases were reported. Maximum cases (48.12%) were between 21-40 years age group. Maculopapular rash (57.21%) was the most common pattern of CADR followed by fixed drug eruption (24.06%). Diclofenac (9.90%) was the most common offending drug followed by paracetamol (7.2%). Overall, anti-microbial drugs (24.59%) constituted maximum number of CADRs.
Conclusion- A wide clinical spectrum of CADRs ranging from maculopapular rash to serious Steven Johnson syndrome (SJS) was observed. Overzealous use of the drugs should be avoided, and proper ADR monitoring should be done for patient safety.
Downloads
References
Badar V, Parulekar VV, Garate P. A surveillance study of cutaneous adverse drug reactions in a tertiary care teaching hospital in India. International Journal of Basic & Clinical Pharmacology. 2018 Dec;7(12):2439.
Manjhi PK, Mohan L, Dikshit H, Mishra H, Kumar M,Shambhu D. IJBCP International Journal of Basic and Clinical Pharmacology Original Research Article Drug utilization pattern in dermatology outpatient department at a tertiary care hospital in Navi Mumbai. 2017;6(3):559-62.
Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions.A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358–63.
Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53:2–8.
Panja B, Mukherjee S, Goswami D, Bhushan B, Bhattacharjee S, Sen S. Study of Clinicodemographic Profile of Adverse Cutaneous Drug Reactions in Indian Perspective.
Sacerdoti G, Vozza A, Ruocco V. Identifying skin reactions to drugs. Int J Dermatol 1993;32:469-78
Pudukadan D, Thappa DM. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian Journal of Dermatology, Venereology & Leprology. 2004 Jan 1;70(1).
Brar BK, Kaur J, Kumar S, Sethi N, Kumar R. Cutaneous adverse drug reactions profile in a tertiary care hospital in North India. Journal of Pakistan Association of Dermatologists. 2017;27(2):158-63.
Rath B, Naik MR, Rath B, Bhoi R, Prakash J. Cutaneous adverse drug reactions in a tertiary care hospital: an observational study. Journal of pharmacovigilance and drug research. 2020 Sep 1;1(1):6-9.
Qayoom S, Bisati S, Manzoor S, Sameem F, Khan K. Adverse cutaneous drug reactions – a clinic-demographic study in a tertiary care teaching hospital of the Kashmir Valley, India. Arch Iran Med. 2015;18:228-33.
Mahatme N, Narasimharao R. A study of clinical patterns and causative agents of adverse cutaneous drug reactions. Indian Journal of Drugs in Dermatology. 2016 Jan 1;2(1):13.
Noel MV, Sushma M, Guido S. Cutaneous adverse drug reactions in a hospitalised patients in a tertiary care center. Indian J Pharmacol 2004;36:292-5.
Mokhtari F, Nikyar Z, Naeini B, Esfahani A, Rahmani S. Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients. J Res Med Sci. 2014;19:720–5.
Dhar S, Banerjee R, Malakar R. Cutaneous drug reactions in children. Indian J Paediatr Dermatol. 2014;15:5–11.
Puavilai S, Timpatanapong P. Prospective study of cutaneous drug reactions. J Med Assoc Thai. 1989;72:167–71.
Amrinder R, Kaur I, Singh J, Kaur T. Monitoring of cutaneous adverse drug reactions in a tertiary care hospital. J Pharmacovigilance. 2016;4:207.
Faiza Al-Raaie, Banodkar DD. Epidemiological study of cutaneous adverse drug reactions in Oman. Oman Med J. 2008;23:21–7.
Sharma R, Dogra D, Dogra N. A study of cutaneous adverse drug reactions at a tertiary center in Jammu, India. Indian Dermatol Online J. 2015;6:168–71.
BHANUSHALI SP, PHULARI YJ, HIREMATH RN, KANDPAL R, PATEL P. A clinical-etiological study of adverse cutaneous drug reactions at tertiary care center in south India. Asian J Pharm Clin Res. 2022;15(4):71-6.
Nagaraju N, Puneetha. The current trend of cutaneous drug reactions at a tertiary care hospital. Int J Res Dermatol. 2019;5(2).
Rana S, Gupta K, Agarwal N, Ahamed AN. A study of cutaneous adverse drug reactions and their association with autoimmune diseases at a tertiary centre in South-West Rajasthan, India. Indian Journal of Dermatology. 2021 Jul;66(4):445.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol 2013;79:389-98.
Ma L, Du X, Dong Y, Peng L, Han X, Lyu J, Bai H. First case of Stevens-Johnson syndrome after rabies vaccination. Br J Clin Pharmacol. 2018 Apr;84(4):803-805.
Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2022 Nov;36(11):1947-68.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Dr. Tejinder Kaur, Dr. Nikita Margam, Dr. Gurpreet Kaur Randhawa
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.